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Abstract 
OBJECTIVES Rising costs in oncology care often impact patients and families directly, 
making communication about costs and financial impacts of treatment crucial. Cost 
expenditures could offer opportunities for estimation and prediction, affording 
personalized conversations about financial impact. We sought to explore providers’, 
patients’, and caregivers’ preferences towards implementing communication about cost, 
including when, how, and by whom such information might be provided.  
METHODS We conducted semi-structured phone interviews with a diverse population 
including 12 oncology providers, 12 patients, and 8 patient caregivers (N=32). The 
constant comparative method was used to identify mutually agreed upon themes.  
RESULTS Participant groups differed in their concerns surrounding cost 
communication, namely whether they want to receive this information and how such 
information might impact provider and patient treatment decisions. All participants 
agreed that oncology providers should not be leading cost conversations. Patients and 
caregivers identified social workers or financial advisors as most equipped to 
communicate about cost. Participants emphasized timely cost conversations, ideally 
around the time of diagnosis. Participants favored various metrics of financial impact 
beyond overall costs of care including disability, days lost from work, and out-of-pocket 
expenses.  
CONCLUSION Cost transparency should be incorporated in usual care however, there 
are several challenges to making cost conversations a part of everyday practice. 
Patients and family members need resources related to cost to aid in decision making 
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and those delivering cost information should have competency in oncology, financial 
advisement, and patient-centered care.  
 
Keywords: financial toxicity, cost estimates, qualitative research, cancer care, patient-
provider communication, implementation 
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Introduction 
Out of pocket costs in cancer care are skyrocketing along with a burgeoning number of 
treatments that test the tolerance of health systems and patient-family affordability.[1-3] 
In the US, although there are new treatment options for most types of cancer, the cost 
disparity for this illness has increased dramatically while health insurance coverage has 
become less reliable, often resulting in patients (and their families) becoming 
responsible for a greater portion of their care through co-pays and co-insurance.[4] Due 
to the rise in both out-of-pocket and system-wide costs, organizations including the 
American Society of Clinical Oncology (ASCO) and the Institute of Medicine emphasize 
communication between patients and physicians about cancer costs as a standard 
practice for high-quality care.[5,6] There is hope that communicating about costs might 
reduce unnecessary expenditures in diagnostic testing and lead to identifying cost-
reducing treatment options.[7] Further, recent research finds that discussing costs with 
patients is associated with improved patient satisfaction and may influence patient 
decision-making.[8-10] Despite support for discussing costs, there is no consensus on 
what constitutes best practices.  
In the U.S., precisely estimating individual costs of care is difficult due to 
differences in coverage, conditions, and health care networks. Uncertainty about costs 
of care generated by a particular set of treatments may further impair the 
meaningfulness of introducing the subject of cost in healthcare encounters.[11] 
Predictive modeling or big data analytics, which is more commonly used for estimating 
prognosis, is beginning to crossover into evaluating cost outcomes.[12] Cost 
estimations are currently restricted to major health insurance programs such as 
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Medicare. However, it is likely that these cost estimate tools will reach a broader 
population as the need for this information continues to grow.[13] Furthermore, 
important aspects of treatment such as charges for specific high-cost drugs or work-
related disability may be feasible, even if overall costs remain elusive to predict.   
 Therefore, it is critical to identify how to effectively navigate patient-provider 
conversations about costs and financial impacts of cancer treatment. Many patients and 
families desire to discuss and understand treatment costs.[14] On the other hand, most 
providers are underprepared and uncomfortable leading such discussions.[15] Further, 
the timing of when to discuss costs is not well documented.[16] Ethical issues also arise 
as patients and providers alike express concerns for how cost and financial information 
could impact treatment choices.[7] Given the rising financial liability that patients and 
families face for cancer care, and the growing potential of predictive analytics, we set 
out to explore providers’, patients’, and their caregivers’ preferences related to 
discussing cost and other financial impacts of cancer care.  
Informed by the Consolidated Framework for Implementation Research, we 
interviewed participants to characterize important aspects of implementing routine cost 
communication including when, how, and by whom such information should be 
communicated.[17] 
Methods 
We conducted 32 semi-structured phone interviews with patients (n=12), providers (i.e., 
chaplain, social workers, nurses, physicians; n=12), and caregivers (n=8) from Stanford 
University outpatient oncology clinics. The goal was to recruit a diverse number of 
providers as well as include the patient and family member voice. Rather than 
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comparing disciplinary and patient – family perspectives definitively, we had the goal of 
exploring the range of perspectives regarding cost communication in cancer care. We 
focused on implementation, and developed our questions to reflect elements of the 
Consolidated Framework for Implementation Research.[17,18]  
We recruited participants through the oncology department, clinic email 
announcements, and online listservs. Eligible providers, patients, and caregivers were 
at least 18 years of age and provided or received care at the Stanford Cancer Centers. 
The study sample included mostly Females (71%) of White/Caucasian decent (80%). 
Table 1 provides a breakdown of cancer types among patients and caregivers of 
patients as well as provider specialty. Health conditions among patients ranged from 
remission from chronic lymphocytic leukemia to persistent low-grade ovarian cancer on 
hospice. Most patients were insured. The majority of providers were oncology clinicians 
(73%) with work ranging in neuro-oncology, hematology, bone marrow transplant, and 
palliative care (see Table 1). We provided a $25 incentive to patient and caregiver 
participants. The Stanford University Institutional Review Board (IRB) approved this 
study and all participants completed oral consent before participating.  
We conducted and recorded interviews over the phone, and later transcribed 
them verbatim using a professional transcription service. Following the development 
and piloting of an interview guide informed by the Consolidated Framework for 
Implementation Research (CFIR),[17,18] the first and second authors conducted 
interviews between December 2016 and May 2017. Interview questions were consistent 
across the three participant groups (see Appendix 1 for Interview Guide). Interviews 
lasted approximately 45 minutes and addressed diverse topics relevant to 
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communication in the cancer encounter. We discussed the general application of 
prognostic information, patient-family centered outcomes, and communication about 
costs of care in the cancer encounter. Interviews covered general perceptions (e.g., 
how information might affect treatment decision-making), how information should be 
provided (i.e., features of communication), and how cost communication might be 
implemented in practice.  
We analyzed transcripts using the constant comparative method and coded text 
where participants reflected on aspects related to costs. Following preliminary analyses, 
the lead author (M.H.) developed a tentative codebook based on thematic saturation. 
Another research team member (A.S.) applied and refined the codebook and met with 
the lead author to confirm codes and sub-categories. A third member of the research 
team (A.N.) separately analyzed the data using the revised codebook. All three team 
members reconciled their coding across transcripts to confirm key themes. A fourth 
member of the research team (C.G.) examined quotes representative of each code and 
helped resolve discrepancies with the lead author. All analyses used Atlas.ti software.  
Results 
We identified four main thematic domains related to implementing cost communication 
across participant groups: benefits of cost information; potential drawbacks to having 
cost information; who would deliver this information (including conversational 
characteristics); and the timing for delivering cost information. Table 2 provides practice 
insights for each domain based on themes reflected across all three groups. 
Benefits of Cost Outcome Information  
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Participants generally agreed that the possibility of predicting the costs of cancer care 
was desirable, largely because it would allow patients and families to prepare financially 
for the impending expense of treatment(s). Among the patient and caregiver 
participants, having access to future costs of care also afforded them the ability to 
decide whether or not they should pursue a particular type of treatment. 
“I think the out [of] pocket cost is important for people who leave family behind. 
And being sure that their loved ones that are left behind have adequate finances 
to continue. It may be that the cost is simply not worth the predicted results of the 
treatment.” (Patient, Chronic Lymphocytic Leukemia) 
Providers also thought that cost information could prepare patients and families 
financially, allowing for a much better patient experience.  
“So if they [patients] have a fairly predictable way of looking at that [cost], they 
[patients] have some financial resources, they [patients] know that they’re going 
to be able to meet this need, it’s not going to cost them [patients] their bank 
account, that’s going to make a much better patient experience than the surprise 
where we just see people drop off the map." (Provider, Chaplain) 
Potential Adverse Effects of Cost Outcome Information  
Participants also raised several concerns should costs and financial impact predictions 
become readily available. Some feared providing such information might negatively 
impact treatment choices.  
“For me, I think I would rather they [provider] not disclose the cost…Because it 
makes me feel less liability, so I can focus on the treatment. Because actually, 
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without knowing the cost, I would choose the best treatment for myself. If I know 
the cost, then I might have a second doubt.” (Patient, Acute Lympho Leukemia) 
Some participants took issue with how cost information would be used, and in particular, 
patients were largely concerned about the potential for cost information to influence 
what treatment options providers offer.  
“…I think I would want that [cost estimates], but I wouldn’t want it at the expense 
of bureaucrats or even my provider deciding a priority that something is too 
expensive and therefore—we’re not even going to consider that.” (Patient, Brain 
Cancer) 
Conversely, providers worried that patients might misinterpret predicted cost estimates.  
“My only concern would be that they [patients] interpret it, just like any data, 
incorrectly. I think some clinicians or people in the healthcare field would say, 
‘Well, we shouldn’t talk about costs at all.” (Provider, Palliative Care Physician) 
Another widely expressed concern among participants from all three interview groups 
was the impact that cost predictions could have on decision-making. Specifically, 
participants were concerned that cost predictions may force providers to make a choice 
between what is good for the health of the patient, and what may be most beneficial on 
a financial level.   
“There are a lot of different ways you can use data to drive different outcomes. 
And if I’m [the provider] using this to make the hospital look better, if I’m using 
this to drive down my costs, if I’m using this for purposes other than what’s best 
for the patient and what’s best for the family, then there is a danger there.” 
(Family, Husband of Patient) 
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“I think part of it would be…my own kind of moral distress around if I’m going 
through different options and one option’s really expensive and knowing or 
seeing that I felt like it’s the right plan, if I say I may not go with that option or 
choose that option because of financial reasons how would that make me feel 
from my perspective?” (Provider, Palliative Care Physician)   
Delivery of Cost Outcome Information 
Participants highlighted ideal characteristics that the deliverer of cost information should 
possess, including empathetic communication skills, knowledge of finances and 
financial planning, and clinical expertise in the management of the cancer as well as 
potential treatment options.  
“[It should be] somebody that has those qualities that…they’re sensitive to the 
issues that the person is facing. And, and knowledgeable about the organization 
and…a little bit of knowledge about the disease itself.” (Patient, Lung Cancer) 
Participants identified several reasons why clinicians should not be tasked with sharing 
cost information with patients and their families. Reasons include lacking familiarity with 
the financial system, as well as not wanting to divert provider focus away from the 
health of the patient.  
“I honestly think it’s better if [communicating cost information] is separate from 
the treatment team just because I think that it’s kind of important for patients to 
know that when you’re looking up [that] you’re not really looking at the dollars 
and that kind of thing, and generally we’re not. I mean, right now we don’t really 
get a lot of direct information about it. But I think the patient would reasonably be 
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concerned that if we start talking to them about the cost of things as their 
physician then it kind of compromises our role to just kind [of] advocate for what 
we think the best treatment is.” (Provider, Blood Marrow Transplant Physician) 
Participants most frequently identified social workers as the healthcare professionals 
perhaps most equipped to deliver cost outcome information. However, some 
participants noted that there are currently no suitable professional roles among health 
care staff to execute this work. Instead, they suggested that this might necessitate an 
entirely new professional role.  
“It’s someone that—it’s almost like it’s a unique thing. I don’t see nursing doing it; 
I’d have the same worries. You know, the medical assistants are already busy 
doing stuff for new patients. Like, it would almost be like a separate person.” 
(Provider, Palliative Care Physician) 
Timing of Cost Outcome Information 
Due to the sensitivity of receiving a cancer diagnosis, deciding when to deliver 
information about predicted costs of treatment is particularly important. There was some 
variability across participant responses around optimal timing, with some participants 
preferring to wait and others wanting cost information as early in the cancer journey as 
possible. A common thread among the responses surrounding timing was readiness to 
receive this information, which many noted was best done after patients and family 
members had time to absorb and come to terms with the cancer diagnosis and 
prognosis.   
“I would put it in after the tests have been run and after the surgeon’s really 
gotten a good chance to examine me. Take a good look, do a repeat visit if 
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necessary but at that, at the point at which I’ve been seen, it’s been diagnosed, 
everybody’s got a really good grip on what it is. I think at that point people should 
have an option [for cost information].” (Patient, Papillary Thyroid Cancer) 
 
“I don’t think it should be at the time, at the delivery of diagnosis. I think that 
patients and family members might need a little bit of time to let things soak in, 
but as treatment decisions are made or discussions are talked about what’s 
down the road…that would be useful.” (Family, Wife of Patient) 
Participants also noted the need to revisit cost estimates as patient health or treatment 
options progress and possibly change. Waiting for patients to express interest in cost 
information was likely too late, as the following comment from a provider emphasizes:  
“The biggest decisions happen at the time of diagnosis and initiation of therapy. 
So, that would be the logical time. I guess this is sounding a little bit obvious, but 
any time before we change therapy, we’d want to reevaluate and see that [cost] 
information…Waiting until there was an impact or until the patient expressed 
concern, I think those…are too late. That’s currently what we’re doing and that’s, 
I think, a disservice to patients and their families.” (Provider, Clinical 
Hematologist) 
Discussion 
We evaluated what oncology providers, patients, and family members feel about how 
cost communication should be implemented in practice. Participants identified important 
considerations for incorporating information about treatment cost and financial impacts 
into routine cancer care. Availability of individualized cost estimates would facilitate 
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financial preparation, potentially reduce the use of excessive treatments, and likely 
afford a better patient experience. Concerns were raised about how cost information 
could adversely affect patient-provider decision-making, the possibility of patients 
misinterpreting cost data, and the ethical dilemmas that access to cost information could 
present. Participants elaborated on characteristics a person delivering cost information 
should possess, and appropriate timelines for discussing costs of care.  
Clinicians, patients, and families agreed that cost information could help families 
prepare, but clinicians and patients both raised concerns about negative impacts on 
decision making. Preparation for financial jeopardy is indeed important, as clinicians 
noted that high costs may affect compliance with treatment adversely.[19] Patients 
pointed to the risk of debt from treatments or “financial toxicity” as an important 
consideration for quality of life.[20] Participants’ concerns echo previous research that 
highlight the various ways in which cost information may negatively impact and/or 
complicate treatment decision-making.[11] Alternatively, availability of cost information 
may not necessarily impact which treatments patients choose.[14] Our findings also 
suggest that providers may be ill equipped to carry out cost conversations, and in some 
instances they prefer not to have these discussions. Given participant concerns about 
system-level cost priorities overriding patient and family level priorities, there is likely still 
a need for discussions at some point, between the patient (and family) and health care 
provider to ensure transparency when recommendations are made to the patient 
regarding treatment choice. 
Concerns about negative impacts of introducing cost information in the patient-
physician encounter reflect a realistic concern that patients may choose to safeguard 
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the financial wellbeing of loved ones over their own health outcomes. In the SUPPORT 
Study, patients indicated that they would be willing to forgo life-sustaining treatments if 
continuing to use them jeopardized the financial health of their family.[21] The continued 
erosion of safety nets (e.g., Affordable Care Act) is placing more in the crosshairs of 
medical bankruptcy.[22] Given that patients themselves care deeply about these issues 
and the impact of their choices on loved ones, it seems imperative to offer cost 
discussions in order to provide patient-family centered cancer care. Further, one could 
argue that it may be unethical not to assess the financial consequences of cancer 
treatment with patients.[23] Our participants pointed to the need for a clear point person 
who can deliver cost information, potentially the social worker, and also suggested 
specific guidance (e.g., the timing) related to such discussions. 
These suggestions that someone other than the physician deliver cost 
information to patients contrasts with previous research.[11] Physicians face several 
challenges in the context of delivering cost information that may contribute to their 
general reticence to engage in cost conversations and elucidate why other healthcare 
professionals may be more equipped. Among these challenges include a lack of 
knowledge regarding costs of treatment and coverage options specific to an individual 
patient and minimal or no training on when and how to deliver cost information.[24-26] 
Physicians may also struggle to navigate tensions between treatment options and cost 
that could have potential implications on decision-making.[27,28] Given the ethical 
concerns and physicians’ potential lack of understanding regarding accurate costs of 
treatment demonstrated in our study and others,[29] designating someone other than 
the physician may have greater utility.  
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A variety of staff other than physicians may be best suited for this task with 
appropriate training. Social workers, case managers, navigators, and others have the 
potential to play expanded communication roles and might be considered depending on 
health care setting, staffing, and goals of a particular cost communication intervention. 
Often, these professional roles already undergo training to deliver patient and family 
centered care. In addition, their responsibilities do not intrude on the technical disease-
focused advocacy of the physician in the patient-physician relationship, freeing them 
from some of the ethical constraints that physicians may face in decision making. 
Further research is needed to identify the training, information, and preparation that 
teams need to properly engage patients and family members about costs. Notably, 
participants signaled the importance of addressing other ways cancer care may impact 
finances, including disability, inability to work, and out-of-pocket costs. These 
preferences may be a helpful starting point for addressing patients’ and families’ cost 
concerns as it relates to their specific health trajectory.   
There were a few subtle differences across the three participant groups. The 
potential adverse effects of the availability of cost outcome information presented the 
greatest discrepancy between patients/caregivers and providers. While patients and 
caregivers expressed concerns about how cost information would influence the 
providers decision-making in terms of what treatment options they would present to the 
patient, providers were concerned about patients misunderstanding of cost outcome 
data. Similarly, Aakhus et al. found that patients worried about profiling based on their 
ability to pay and providers expressed concerns surrounding personal or institutional 
conflicts of interest.[30] Again, training a member of the health care team who works 
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alongside the physician (but is not the physician) to provide cost information to patients 
and caregivers as part of the cancer care experience may minimize these concerns. 
There may also be alternative resources to help support navigating the costs of cancer 
care such as survivorship plans, which provide patients with information on estimated 
direct and indirect costs as well as ongoing care.[31] Survivorship plans could become a 
standardized tool for accompanying cost discussions. 
Our study has several limitations including that we evaluated a single Cancer 
Center with a high prevalence of insured patients. Despite that, our cohort of patients, 
caregivers, and providers generally emphasized the importance of cost communication. 
We did not achieve a sufficient sample to compare the responses of providers by 
discipline; nevertheless, our study represents the range of responses among a diverse 
set of clinical and patient-family stakeholders with regard to cost communication. Our 
findings from a predominantly female, White/Caucasian sample may not reflect the 
experiences among other genders and individuals who identify as other race/ethnicities. 
Relatedly, differences that we observed preliminarily between groups require additional 
study of larger samples. Our work was qualitative, so it does not represent the 
prevalence of these issues, but because we structured our questions using an 
implementation framework, it provides important insights into the matrix of concerns 
relevant to successful intervention.[32]  
In summary, our work supports the emphasis expressed by ASCO and other 
societies who have endorsed patient communication around cost impacts as an element 
of patient-family centered care. It highlights the need for team-based, financially 
informed, and interpersonally competent approaches to communicating such 
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information as well as expresses the need for educating the lay public, not just cancer 
patients and families, about medical costs and participatory decision making. Our work 
also points to outcomes to track in terms of assessing both the benefits and unintended 
consequences of cost communication.  
Provider concerns regarding their own moral distress also captures a critical, 
clinical, and societal issue surrounding cost versus benefit. Though each case must be 
handled on a one-to-one basis, society can affect change in terms of ensuring 
comprehensive health care support. More research and discussion in this area is 
warranted. Collectively, findings underscore the cost impacts encompassing disease, 
decisional, and patient-family goals as outcomes for research. Interventional research is 
warranted to further understand practices for integrating cost conversations into usual 
cancer care.  
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Table 1. Participant Cancer Specialty and Type  
 
 Providers Patients Caregivers 
1 Chaplain to oncology 
outpatient palliative medicine 















4 Social Worker in bone 
marrow transplant 
Leukemia bone marrow 
transplant (remission) 
Brain cancer 
5 Social Worker in the infusion 
treatment area 
ALL leukemia with bone 
marrow transplant and 
CAR T-cell therapy 
Did not disclose 
6 Neuro-oncologist Brain cancer Did not disclose 
7 Palliative care physician in 
cancer center 
Brain cancer Prostate cancer 
8 Clinical Hematologist Papillary thyroid cancer Endometrial cancer 
9 Nurse Coordinate in bone 
marrow transplant area 
Ovarian cancer (hospice)  
10 Palliative care physician in 
cancer center 
Lung cancer  
11 Bone marrow transplant 
physician 
Cervical cancer (hospice)  
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Table 2. Insights for Practice 
 
Domain Takeaway 
Benefits of Cost Outcome Information 
• Ability for patients to prepare 
impending treatment 
• Decrease excessive treatment 
spending 
• Better patient experience through 
cost transparency 
Potential Adverse Effects of Cost 
Outcome Information 
• Concern for influence on provider 
treatment choice 
• Concern for patient 
misinterpretation of cost 
information 
• Ethical dilemma in access to cost 
estimates in terms of treatment 
choice and decision making 
Delivery of Cost Outcome Information 
• Role of the Social Worker in 
assisting with cost information 
delivery 
• Compassionate approach to 
delivery of cost information 
• Individual relaying cost information 
must be knowledgeable on health 
condition and financial systems 
Timing of Cost Outcome Information 
• Not at the time of diagnosis 
• Early in the disease, after the 
patient, family, and health care 
team has had time to assess the 
prognosis 
• Reevaluation of costs of care when 
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Appendix 1. Interview Guides 
Provider: As you know out of pocket costs and other indirect expenses to patients or 
families can be substantial, especially with newer treatments or if one considers the 
impact of caregiving on a family members job. One of the considerations in improving 
information to patients, based on planned or anticipated care, or perhaps modeling 
future care is to think about providing information to patients and families about the 
costs they will bear.  
1. Assuming we can make predictions about costs, what information would you like 
to see provided to you? (OOP costs? Healthcare system costs?) 
a. When would you like to see cost information? 
2. Assuming we can make predictions about costs, what are your thoughts on 
providing OOP cost information to patients? What about healthcare system 
costs?  
a. When do you think that information should be presented to patients?  
3. How do you feel about personally delivering this information to patients?  
a. If not you, who should be the one to deliver information about costs?  
b. How do you think this information should be communicated?  
4. In what ways might this change how you approach treatment options? 
 
Patient: Patients and families face very different costs for the treatment they are 
undergoing and cancer medications are getting increasingly expensive. Using the same 
information, doctors may be able to tell how much your treatments and future care are 
likely to cost. 
1. How would you feel if we could predict your health care system costs for 
treatments and future care?  
2. How would you feel if we could predict your out of pocket costs for treatments 
and future care? Or the lost income or expenses your family might face as a 
whole?  
3. Who do you believe should deliver cost information to patients and their family 
members and at what point should cost information be provided? 
4. In what ways might this change how you approach treatment decisions? 
 
Caregiver: Patients and families face very different costs for the treatment they are 
undergoing, and cancer medications are getting increasingly expensive.  
1. How would you feel if we could predict health care system costs for your loved 
one’s treatments and future care?  
2. How would you feel if we could predict the out of pocket costs for your loved 
one’s treatments and future care? Or the lost income or expenses your family 
might face as a whole?  
3. Who do you believe should deliver cost information to patients and their family 
members and at what point should cost information be provided? 
4. In what ways might this change how you approach treatment decisions? 
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